快速分子诊断指导铜绿假单胞菌对头孢他啶/阿维巴坦和头孢洛扎/他唑巴坦的经验性用药:PRIMERS IV
本研究使用197株异质性铜绿假单胞菌(含多重耐药分离株),评估两种快速分子诊断(Acuitas Resistome试验和VERIGENE革兰阴性血培养试验)能否识别对头孢他啶/阿维巴坦(CZA)和头孢洛扎/他唑巴坦(TOL/TAZO)的敏感性。结果显示,两种平台对BL-BLI敏感性的灵敏度均为100%(95%CI 97%-100%),但对耐药性的检测灵敏度较低:TOL/TAZO为66%(95%CI 52%-78%),CZA为33%(95%CI 20%-49%)。结论认为,这些诊断平台在检测到耐药基因或耐药基因未检测到且已知耐药率低的情景下最有潜力。
要点
- 快速分子诊断对CZA和TOL/TAZO敏感性的灵敏度均为100%,可支持经验性用药选择。
- 对耐药性检测灵敏度较低:TOL/TAZO 66%,CZA 33%,需警惕假阴性。
- 经验性决策应结合当地耐药流行率,耐药率随时间地域变化。
核心结论
- 快速分子诊断平台在检测到耐药基因或耐药基因未检出且已知TOL/TAZO或CZA耐药率低的情景下最具潜力。
- 临床医生需认识到基于耐药基因检测的经验性治疗决策受耐药流行率影响,且耐药率随时间地域变化。
研究设计与样本
- 使用197株异质性铜绿假单胞菌(包括多重耐药分离株)评估两种快速分子诊断(Acuitas Resistome试验和VERIGENE革兰阴性血培养试验)识别对CZA和TOL/TAZO敏感性的能力。
主要发现
- 两种平台对BL-BLI敏感性的灵敏度均为100%(95%CI 97%-100%)。
- 对TOL/TAZO耐药性的检测灵敏度为66%(95%CI 52%-78%)。
- 对CZA耐药性的检测灵敏度为33%(95%CI 20%-49%)。
关键数值与推荐
- 敏感性灵敏度:100%(95%CI 97%-100%),适用于CZA和TOL/TAZO。
- 耐药性灵敏度:TOL/TAZO 66%(95%CI 52%-78%);CZA 33%(95%CI 20%-49%)。
临床怎么用
- 在耐药基因检测到或耐药基因未检测到且已知耐药率低时,可考虑依据快速分子诊断结果经验性使用CZA或TOL/TAZO。
- 临床决策需结合当地耐药流行率,并注意耐药检测灵敏度较低带来的假阴性风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Overcoming β-lactam resistance in pathogens such as Pseudomonas aeruginosa is a major clinical challenge. Rapid molecular diagnostics (RMDs) have the potential to inform selection of empiric therapy in patients infected by P. aeruginosa. METHODS: In this study, we used a heterogeneous collection of 197 P. aeruginosa that included multidrug-resistant isolates to determine whether 2 representative RMDs (Acuitas Resistome test and VERIGENE gram-negative blood culture test) could identify susceptibility to 2 newer β-lactam/β-lactamase inhibitor (BL-BLI) combinations, ceftazidime/avibactam (CZA) and ceftolozane/tazobactam (TOL/TAZO). RESULTS: We found that the studied RMD platforms were able to correctly identify BL-BLI susceptibility (susceptibility sensitivity, 100%; 95% confidence interval [CI], 97%, 100%) for both BLs-BLIs. However, their ability to detect resistance to these BLs-BLIs was lower (resistance sensitivity, 66%; 95% CI, 52%, 78% for TOL/TAZO and 33%; 95% CI, 20%, 49% for CZA). CONCLUSIONS: The diagnostic platforms studied showed the most potential in scenarios where a resistance gene was detected or in scenarios where a resistance gene was not detected and the prevalence of resistance to TOL/TAZO or CZA is known to be low. Clinicians need to be mindful of the benefits and risks that result from empiric treatment decisions that are based on resistance gene detection in P. aeruginosa, acknowledging that such decisions are impacted by the prevalence of resistance, which varies temporally and geographically.
引用
- Evans SR, Tran TTT, Hujer AM, et al. Rapid Molecular Diagnostics to Inform Empiric Use of Ceftazidime/Avibactam and Ceftolozane/Tazobactam Against Pseudomonas aeruginosa: PRIMERS IV. Clin Infect Dis. 2019. PMID: 30239599. doi:10.1093/cid/ciy801
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。